奥拉西坦联合依达拉奉治疗急性脑梗死的临床疗效及对血清炎症因子的影响  

Effect of oxiracetam combined with edaravone on clinical efficacy and serum inflammatory factors in patients with acute cerebral infarction

作　　者：许红[1] 华烨[1] 冯志强[1] 吴双双[2] 马涛[1] 刘宇敏[1] 陆云南[1] XU Hong;HUA Ye;FENG Zhigang;WU Shuangsliuang;MA Tao;LIU Yumin;LU Yunnan(Department of Neurology, the Affiliated Wuxi Second People＇s Hospital,Wuxi, Jiangsu, 214000;Jianysu People＇s Hospital, Nanjing, Jiangsp, 210000)

机构地区：[1]江苏省无锡市第二人民医院神经内科,江苏无锡214000 [2]江苏省人民医院,江苏南京210000

出　　处：《实用临床医药杂志》2017年第19期31-33,共3页Journal of Clinical Medicine in Practice

基　　金：2015年江苏省干部保健科研课题(BJ15018)

摘　　要：目的观察奥拉西坦联合依达拉奉治疗急性脑梗死的临床疗效及其对血清炎症因子的影响。方法采用随机数字表法将68例急性脑梗死患者平均分成观察组和对照组。2组患者均采用常规的抗脑卒中治疗。对照组给予依达拉奉治疗,观察组在对照组基础上加用奥拉西坦治疗。观察2组患者的临床疗效、不良反应发生情况和治疗前后的NIHSS评分、血清C反应蛋白(CRP)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)水平的变化。结果观察组和对照组的总有效率分别为94.12%和76.47%,观察组的总有效率显著高于对照组(P<0.05)。2组患者的NIHSS评分以及血清CRP、IL-6、TNF-α水平在治疗后均显著降低(P<0.05),且治疗后观察组的NIHSS评分以及血清CRP、IL-6、TNF-α水平均显著低于对照组(P<0.05)。结论采用奥拉西坦联合依达拉奉治疗急性脑梗死,不仅能够明显降低患者的血清CRP、IL-6、TNF-(水平,还可以明显改善患者的神经功能缺损程度。ObjectiveTo observe the effect of oxiracetam combined with edaravone on clinical efficacy and serum inflammatory factors in patients with acute cerebral infarction and their influence on serum inflammatory factors. MethodsA total of 68 patients with acute cerebral infarction were equally divided into observation group and control group by random number table method. All patients were given anti stroke therapy. Patents in control group were given edaravone, while, patients in observation group were given oxiracetam on the base of control group. Then the clinical efficacy and adverse reactions of two groups were observed. The changes of NIHSS, C reactive protein （hs CRP）, interleukin 6 （IL 6）, tumor necrosis factor （ TNF α） levels were also measured. ResultsThe total effective rate of observation group was 94.12% and 76.47% in the control group. The total effective rate of observation group was higher than control group （P〈0.05）. Both the basic cure rate and significant progress rate of observation group were also less than control group （P〈0.05）. The NIHSS, CRP, IL 6 and TNF α levels of patients in two group decreased after treatment （P〈0.05）, and those indexes of observation group were much lower than that in the control group after treatment （P〈0.05）. ConclusionTreatment of oxiracetam combined with edaravone in patients with acute cerebral infarction can reduce the NIHSS and serum CRP, IL 6, TNF α levels, and improve neurologic impairment.

关 键 词：奥拉西坦 依达拉奉 急性脑梗死 炎症因子 

分 类 号：R743[医药卫生—神经病学与精神病学]